Freenome vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major investor; signed a $75M exclusive license with Exact Sciences for colorectal cancer;
About
Freenome is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California. The company is developing a multiomics blood-based testing platform for the early detection of cancer — combining genomics, proteomics, metabolomics, and epigenomics signals from a single blood draw and applying AI/ML models to distinguish cancer-derived signals from normal biological variation. Its lead program targets colorectal cancer (CRC) screening, aiming to provide a non-invasive alternative to colonoscopy for the millions of Americans who decline or delay guideline-based screening.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.